Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesImmunology/RheumatologyAetna rilonacept (Arcalyst) Coverage Update | Open…
    Ask Trek AI about this page
    CurrentAetnaPolicy 0770

    Rilonacept (Arcalyst) coverage

    Customize your policy alerts

    Sign up for Aetna Policy 0770 alerts

    Get alerted when Policy 0770 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's medical necessity, prescriber requirements, dosing, and coding for rilonacept (Arcalyst) for CAPS, DIRA maintenance, and recurrent pericarditis, and lists experimental/investigational uses. Applies to Aetna coverage determinations.

    Policy Summary
    PayerAetna
    PolicyRilonacept (Arcalyst) coverage
    Policy CodePolicy 0770
    Change TypeMinor update / review
    Effective DateNov 21, 2008
    Last ReviewAug 9, 2023
    Next Review DateJan 25, 2024
    Key ActionObtain prior authorization (HCPCS J2793) and document diagnosis, prior therapies, and a negative TB test within 6 months when initiating therapy.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3FDA-approved indications described
    12 yrsMin age for CAPS & RP
    10 kgMin weight for DIRA
    J2793HCPCS code
    ≥2RP episodes required
    08/09/2023Last review

    Coverage Criteria and Evidence

    Initial Therapy — CAPS

    Covered when ALL of the following are met

    CAPS initial therapy (age >=12): Member has a diagnosis of familial cold auto-inflammatory syndrome (FCAS) with classic signs and symptoms or Muckle-Wells syndrome (MWS) with classic signs and symptoms; AND member has functional impairment limiting activities of daily living; AND member has a documented negative TB test within 6 months if biologic/targeted-synthetic–naïve.age >= 12 years

    Prescriber specialty and TB screening per policy.

    Initial Therapy — DIRA

    Covered when ALL of the following are met

    DIRA maintenance (weight >=10 kg): Member has genetically confirmed IL1RN loss-of-function mutations; AND Arcalyst will be used for maintenance of remission following prior treatment with Kineret (anakinra); AND member weighs at least 10 kg; AND member has a documented negative TB test within 6 months if biologic/targeted-synthetic–naïve when applicable.weight >= 10 kg

    Based on FDA approval and open-label maintenance study dosing and population.

    Initial Therapy — Recurrent Pericarditis

    Covered when ALL of the following are met

    Recurrent pericarditis initial therapy (age >=12): Member is 12 years of age or older; AND member has had at least two prior episodes of pericarditis; AND member has failed at least two agents of standard therapy (e.g., colchicine, NSAIDs, corticosteroids); AND member has a documented negative TB test within 6 months if biologic/targeted-synthetic–naïve when applicable.age >= 12 years; >=2 prior episodes; failed >=2 standard agents

    Prescriber specialty, prior therapy failure and TB screening per policy; clinical response measures for continuation are listed separately.

    Continuation Therapy

    Covered when ANY of the following improvement measures are met for ongoing therapy

    Continuation — CAPS/DIRA/Recurrent pericarditis: Member achieves or maintains a positive clinical response evidenced by low disease activity or improvement in signs and symptoms; For recurrent pericarditis, improvement in any of the following: pericarditic chest pain OR pericardial rubs OR electrocardiogram (ECG) findings OR pericardial effusion OR C-reactive protein (CRP).clinical improvement or decreased recurrence

    Includes new members already on therapy; mirrors continuation criteria in policy.

    Experimental and Investigational / Not Covered Indications

    Not covered (considered experimental/investigational) for the following uses

    Experimental/Investigational uses: Concomitant use of rilonacept with any other biologic drug or targeted synthetic drug; AND use of rilonacept for indications with unestablished effectiveness including adult-onset Still's disease; cardiovascular disorders (acute coronary syndrome, atherosclerosis, Kawasaki disease, myocardial infarction, myocarditis); chronic kidney disease-mineral and bone disorder (CKD-MBD); COVID-19; familial Mediterranean fever; gout (outside trial-supported prophylaxis context); heart failure; inflammatory dermatoses; juvenile idiopathic arthritis; neonatal-onset multisystemic inflammatory disease (NOMID); Schnitzler syndrome; subacromial bursitis; systemic sclerosis; and type-1 diabetes mellitus.effectiveness not established

    See Experimental and Investigational section of policy; concomitant biologic use explicitly considered experimental.

    Covered Indications and trial-derived entry criteria

    Coverage aligned to indications supported by regulatory approval and trial evidence:

    CAPS (FCAS, MWS): Patient with CAPS (FCAS or MWS) consistent with trial entry (clinical diagnosis with classic signs/symptoms) AND patient is 12 years of age or older; rilonacept demonstrated marked clinical improvement and normalization of inflammatory markers in pivotal studies and is FDA-approved for CAPS in patients ≥12 years.age >= 12 years

    Based on phase III CAPS trial and FDA approval.

    DIRA maintenance: Patient with genetically confirmed IL1RN mutations who previously responded to daily anakinra and requires maintenance of remission; dosing in pivotal maintenance study used a loading dose then weekly maintenance with potential escalation as described in study and prescribing information.weight >= 10 kg

    Based on 2-year open-label maintenance study (n=6) and FDA approval.

    Recurrent pericarditis (trial-derived entry criteria):

    Evidence summaries by indication

    Indication-specific evidence summary and implications for coverage decisions:

    Gout — acute flare treatment: Randomized evidence (Terkeltaub et al.) indicates rilonacept added to indomethacin did not provide statistically significant additional pain relief over indomethacin alone, and rilonacept monotherapy provided less pain reduction than indomethacin over 72 hours; therefore rilonacept is not supported as routine treatment for acute gout flares based on available RCTs.RCT evidence

    See Terkeltaub 2013 trial.

    Gout — prophylaxis during initiation of urate-lowering therapy: Phase 3 trials (e.g., PRESURGE-2) showed once-weekly subcutaneous rilonacept (80–160 mg) significantly reduced gout flares during initiation of allopurinol (≈70% fewer flares at Week 16) compared with placebo in populations with ≥2 flares in prior 12 months; safety profile included frequent injection-site reactions.trial population: adults with >=2 flares in prior 12 months; dosing 80–160 mg weekly

    See PRESURGE-2 and related phase 3 data.

    Other (off‑label/investigational) indications — evidence summaries

    Evidence summaries for off‑label or investigational uses (study-level findings):

    Schnitzler syndrome evidence: Prospective, single-center, open‑label study (n=8): loading dose 300 mg SC then 160 mg weekly up to 1 year; rapid clinical response with significant reductions in patient-reported daily health assessments, PGA, CRP and SAA; well tolerated with no treatment-related severe AEs.study-level evidence

    Small uncontrolled study suggests potential efficacy.

    Subacromial bursitis evidence: Randomized, non-inferiority, unblinded single-center study (n=33): single intra-bursal 160 mg rilonacept vs triamcinolone 80 mg; both improved QuickDASH and pain at 4 weeks but triamcinolone was superior (p=0.004 QuickDASH; p=0.044 pain); rilonacept associated with more diarrhea and headache.study-level evidence

    Rilonacept inferior to standard corticosteroid in this trial.

    Systemic sclerosis evidence:

    Requests for concomitant use of rilonacept with any other biologic drug or targeted synthetic drug are considered experimental and investigational because effectiveness of combined biologic/targeted approaches has not been established. Examples listed in the policy include tumor necrosis factor inhibitors and IL-1 agents (e.g., adalimumab, anakinra, etanercept, infliximab, tocilizumab) and targeted synthetics (e.g., tofacitinib).

    Although rilonacept is FDA-approved for CAPS (FCAS and Muckle-Wells syndrome), the policy states that rilonacept has not been studied in NOMID

    Randomized controlled trial evidence does not support use of rilonacept for treatment of acute gout flares. In a trial comparing rilonacept plus indomethacin versus indomethacin alone, addition of rilonacept did not produce a statistically significant incremental pain reduction over indomethacin, and rilonacept monotherapy provided less pain reduction than indomethacin over the 72-hour assessment. Based on these RCT results, rilonacept is not supported for routine treatment of acute gout flares.

    Systematic reviews and current UpToDate summaries for systemic sclerosis do not list rilonacept as a therapeutic option. Although phase I/II studies have evaluated many targeted therapies (rilonacept among them), UpToDate topic reviews of SSc management do not mention rilonacept, indicating it is not an accepted management choice in those reviews.

    The policy considers rilonacept experimental and investigational for numerous off‑label indications where effectiveness is unestablished. Examples explicitly listed include adult-onset Still’s disease, COVID-19, gout (outside trial contexts), Schnitzler syndrome, subacromial bursitis, systemic sclerosis, familial Mediterranean fever, juvenile idiopathic arthritis, cardiovascular indications, and others. Small uncontrolled or early-phase studies exist for some conditions, but the policy deems these uses investigational pending stronger evidence.

    A randomized 12-week trial in patients with stage 3–4 CKD found no meaningful changes in markers of CKD‑MBD or in most measures of physical or cognitive function with rilonacept versus placebo. Because the trial did not demonstrate improvement in biochemical markers or functional endpoints, use of rilonacept for CKD‑MBD or to improve physical/cognitive function in stage 3–4 CKD is unsupported by the available trial evidence.

    Given randomized evidence showing at best no additional benefit or inferior pain reduction compared with standard NSAID therapy for acute gout flares, the policy concludes that rilonacept is not medically necessary as monotherapy or adjunctive therapy for routine management of acute gout flares.

    A phase I trial of rilonacept in recent-onset type 1 diabetes (n=13, 26 weeks) was well tolerated but showed declines in C‑peptide and no convincing preservation of beta‑cell function. The study authors concluded rilonacept is unlikely to be effective as a single agent for preserving beta-cell function in recent-onset T1DM.

    Billing and Coding

    Related CPT CodesCPT
    96372Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular.
    Covered HCPCS Codes (if selection criteria met)HCPCSCovered
    J2793Injection, Rilonacept, 1 mg
    ICD-10 Codes Covered if Selection Criteria MetICD-10Covered
    M04.2Cryopyrin-associated periodic syndromes [age 12 and older]
    M04.8Other autoinflammatory syndromes [Deficiency of interleukin-1 receptor antagonist (DIRA)]
    I30.0 - I30.9Acute pericarditis
    I31.0Chronic adhesive pericarditis
    I31.1Chronic constrictive pericarditis
    I01.0Acute rheumatic pericarditis
    ICD-10 Codes Not Covered for Indications ListedICD-10Not Covered
    D47.2Monoclonal gammopathy [Schnitzler syndrome]
    M06.1Adult-onset Still's disease
    U07.1COVID-19
    No explicit codes in this document segmentmixed
    No codes listed
    TB screening timing — Negative TB test within 6 months of initiating therapy for biologic/targeted-synthetic–naïve persons
    RequirementDocumented negative TB test (PPD, IGRA, or chest x‑ray) within 6 months prior to initiating rilonacept for persons naïve to biologic or targeted‑synthetic drugs.
    Applies toPersons naïve to biologic or targeted‑synthetic therapies who are initiating rilonacept.
    Accepted testsTuberculin skin test (PPD), interferon‑gamma release assay (IGRA), or chest x‑ray as evidence of negative TB status.
    ConsequenceLack of a documented negative TB test within 6 months increases risk of denial of coverage.
    Policy contextPart of initial approval criteria for CAPS, DIRA, and recurrent pericarditis when biologic/targeted‑synthetic naïve.

    Provider Requirements and Prior Authorization

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for HCPCS J2793 (Injection, rilonacept, 1 mg). Coverage is contingent on meeting the policy's clinical criteria and submitting the required documentation below.

    • Prior authorization required: HCPCS J2793 (injection, rilonacept, 1 mg).
    • Coverage contingent on meeting indication-specific and dosing-specific clinical criteria in the policy.
    Prior Authorization

    Indication-Specific Prior Authorization

    Requests must state the specific indication for rilonacept (CAPS subtype: FCAS or MWS; DIRA; or recurrent pericarditis) and include supporting diagnostic documentation as described in the medical necessity criteria.

    • Indication must be specified: CAPS (FCAS or MWS), DIRA, or recurrent pericarditis.
    • Include diagnostic/supporting documentation (e.g., clinical features for FCAS/MWS, genetic confirmation of IL1RN mutation for DIRA, records documenting ≥2 pericarditis episodes for recurrent pericarditis).

    Background, Definitions and Indications

    Rilonacept (Arcalyst) is an interleukin‑1 blocker that acts as a soluble decoy receptor for IL‑1α and IL‑1β. It is FDA‑approved for treatment of cryopyrin‑associated periodic syndromes (CAPS: familial cold autoinflammatory syndrome and Muckle‑Wells syndrome) in adults and children aged ≥12 years, for maintenance therapy in deficiency of interleukin‑1 receptor antagonist (DIRA) for patients meeting weight criteria, and for reduction in recurrence of recurrent pericarditis. Common adverse reactions reported include injection‑site reactions and upper respiratory tract infections.

    CAPS — definition and clinical context
    DefinitionCryopyrin‑associated periodic syndromes (CAPS) are a continuum of autoinflammatory disorders (including FCAS and MWS) caused by NLRP3/CIAS1 mutations leading to IL‑1–mediated inflammation.
    Typical phenotypesIncludes familial cold autoinflammatory syndrome (FCAS) and Muckle‑Wells syndrome (MWS); FCAS is the mildest and NOMID the most severe phenotype.
    PathophysiologyMutations in NLRP3 lead to excessive IL‑1β processing and systemic inflammation; IL‑1 blockade (e.g., rilonacept) targets this pathway.
    Age for FDA approvalRilonacept FDA‑approved for CAPS in adults and children 12 years of age and older.
    Policy Summary
    PayerAetna
    PolicyRilonacept (Arcalyst) coverage
    Policy CodePolicy 0770
    Change TypeMinor update / review
    Effective DateNov 21, 2008
    Last ReviewAug 9, 2023
    Next Review DateJan 25, 2024
    Key ActionObtain prior authorization (HCPCS J2793) and document diagnosis, prior therapies, and a negative TB test within 6 months when initiating therapy.
    SourceLink
    On This Page
    Coverage Criteria and EvidenceBilling and CodingProvider Requirements and Prior AuthorizationBackground, Definitions and Indications
    Patient with recurrent pericarditis with at least two prior episodes who is 12 years or older and who is refractory to or dependent on standard therapy; in RHAPSODY run-in, eligible patients had elevated CRP and required clinical response (e.g., CRP <=0.5 mg/dL and weekly average NRS <=2) to continue in trial.
    >=2 prior episodes; CRP and symptom thresholds per RHAPSODY run-in

    Based on RHAPSODY trial criteria and regulatory review.

    Familial Mediterranean Fever (FMF):
    Limited RCT evidence (Cochrane update) suggests rilonacept did not differ from placebo in number of attacks at 3 months (moderate- to low-certainty evidence); additional high-quality RCTs are needed before routine use can be supported.
    RCT data

    See Yin et al. Cochrane update.

    Schnitzler syndrome: Small open-label prospective studies report rapid clinical responses and reductions in inflammatory markers with rilonacept (e.g., single-center n=8 study), suggesting potential efficacy though evidence is limited and uncontrolled.small uncontrolled studies

    See Krause et al. open-label study.

    Subacromial bursitis: A small randomized unblinded study (n=33) found both intra-bursal rilonacept and triamcinolone improved outcomes, but triamcinolone was superior for QuickDASH and pain at 4 weeks; rilonacept had more diarrhea and headache events.single small RCT

    See Carroll et al. trial.

    Systematic review of targeted therapies in systemic sclerosis included small phase I/II trials of rilonacept but no phase III evidence supporting its use; UpToDate reviews do not list rilonacept as a treatment option, indicating insufficient evidence for routine use.
    literature review evidence

    Investigational in SSc.

    Type 1 diabetes evidence: Phase I trial (n=13) over 26 weeks: rilonacept was well tolerated but mean C-peptide decreased and HbA1c increased modestly; authors concluded rilonacept is unlikely to be effective as a single agent in preserving beta cell function.phase I trial evidence

    Negative for preserving beta-cell function.

    Prior Authorization

    Indication- and Dosing-Specific Prior Authorization

    Some indications require dosing- or context-specific justification (for example, prophylaxis during initiation of urate-lowering therapy for gout). Include indication- and dosing-specific rationale when applicable.

    • For gout flare prevention during initiation of urate-lowering therapy, document prior initiation of urate-lowering therapy and history of ≥2 gout flares in the past 12 months; specify dose regimen requested (e.g., 80 mg or 160 mg weekly).
    • For DIRA maintenance, include prior use of anakinra and rationale for transition to rilonacept and any dose escalation history.
    Note

    Prior Authorization Not Specified in Excerpt

    The excerpt does not list any additional administrative prior authorization codes or separate requirements beyond standard prior authorization for the drug code (J2793) and the clinical documentation requirements noted elsewhere.

    • No other prior authorization codes or administrative steps specified in this excerpt.
    Documentation Required

    TB Screening Requirement

    A documented negative TB screening test (tuberculin skin test [PPD], interferon-gamma release assay [IGRA], or chest x-ray) within 6 months prior to initiating therapy is required for members naïve to biologic or targeted synthetic agents associated with increased TB risk. Positive screens require further evaluation and treatment before therapy.

    • Negative TB test (PPD, IGRA, or chest x-ray) within 6 months prior to initiation for biologic/targeted-synthetic–naïve patients.
    • If TB screening is positive, further testing to rule out active disease is required; do not administer rilonacept for active TB. If latent TB is identified, start TB treatment before initiating rilonacept.
    Denial Risk

    Lack of Clinical Response as a Barrier to Continuation

    Continuation of therapy requires documentation of a positive clinical response. Lack of clinical response is a basis for denying continued therapy.

    • For CAPS and DIRA: evidence of low disease activity or improvement in signs/symptoms.
    • For recurrent pericarditis: improvement in pericarditic chest pain, pericardial rubs, ECG, pericardial effusion, or CRP.
    • Patients who do not meet run-in or response criteria (e.g., as in RHAPSODY/run-in) would not qualify for continued therapy.
    Denial Risk

    Acute Gout Flare — Limited Benefit

    RCT evidence shows limited or no meaningful benefit of rilonacept as monotherapy for acute gout flares compared with standard acute therapies; rilonacept is not supported as a replacement for standard acute gout treatments.

    • Rilonacept showed no statistically significant improvement over indomethacin for acute gout pain in the pivotal trial; therefore it is not recommended as a substitute for standard acute gout therapies (NSAIDs, colchicine, corticosteroids).
    Prior Authorization

    Gout Flare Prevention — Context-Specific

    Rilonacept has demonstrated efficacy for prevention of gout flares when used during initiation of urate-lowering therapy in patients with a history of multiple flares; its use is context-specific and requires documentation of the clinical context.

    • Indicated context for gout: prophylaxis during initiation of urate-lowering therapy (e.g., allopurinol) in patients with ≥2 gout flares in the prior 12 months.
    • Provide documentation of initiation of urate-lowering therapy and prior gout flare history when requesting rilonacept for prophylaxis.
    Note

    None Specified in This Excerpt

    No additional provider actions are specified in this excerpt beyond the clinical and documentation requirements already listed.

    • No other provider actions specified in this excerpt.
    Documentation Required

    Required Clinical Documentation

    Submit required clinical documentation with the prior authorization request to support medical necessity.

    • Diagnosis documentation (e.g., clinical notes supporting FCAS or MWS for CAPS; genetic testing confirming IL1RN mutation for DIRA; records showing ≥2 pericarditis episodes for recurrent pericarditis).
    • Clinical course and prior treatments, baseline and follow-up inflammatory markers (e.g., CRP), and objective findings (ECG, imaging) as applicable.
    Documentation Required

    Diagnosis and Response Documentation

    Provide documentation of the diagnosis and clinical response when applicable to demonstrate both initial eligibility and continued benefit.

    • For DIRA: IL1RN mutation documentation and prior anakinra response/transition notes.
    • For recurrent pericarditis: documentation of clinical response during run-in or treatment (e.g., pain resolution, CRP normalization) and details of prior recurrences.
    Documentation Required

    Gout Prevention Documentation

    When seeking approval for gout prophylaxis during urate-lowering therapy initiation, include documentation specific to gout prevention criteria.

    • Document initiation date of urate-lowering therapy (e.g., allopurinol) and that the patient has had ≥2 gout flares in the past 12 months.
    • Specify the rilonacept dose requested (e.g., 80 mg or 160 mg weekly) and duration of prophylaxis.
    Step Therapy

    Prior Standard Therapies Expected

    Prior therapies expected before rilonacept for recurrent pericarditis include standard agents; documentation of failure or intolerance is required.

    • For recurrent pericarditis, member must have failed at least two agents of standard therapy (examples: colchicine, NSAIDs, corticosteroids).
    • Provide records showing prior use and inadequate response or intolerance to these agents.
    Step Therapy

    Step Therapy for Acute Gout

    For gout indications, step therapy through standard first-line acute treatments is expected prior to considering IL-1 inhibitor therapy for an acute flare.

    • Step through NSAIDs, colchicine, or corticosteroids for acute gout management before considering rilonacept for acute flares.
    • Rilonacept may be considered for prophylaxis during ULT initiation in patients with recurrent flares, not as first-line acute therapy.
    DIRA — definition and clinical context
    DefinitionDeficiency of interleukin‑1 receptor antagonist (DIRA) is a rare autosomal‑recessive autoinflammatory condition caused by loss‑of‑function IL1RN mutations resulting in unopposed IL‑1 signaling.
    Clinical presentationNeonatal‑onset sterile multifocal osteomyelitis, periostitis, neutrophilic pustulosis, periarticular swelling, oral mucosal lesions, and potential life‑threatening systemic inflammation.
    FDA‑approved useRilonacept approved for maintenance of remission of DIRA in patients weighing at least 10 kg, following initial anakinra therapy.
    Evidence basisApproval based on a 2‑year open‑label maintenance study of 6 pediatric patients with IL1RN mutations who had prior benefit from daily anakinra.
    CAPS — additional definition/context entries
    Clinical spectrumCAPS represents a spectrum (FCAS, MWS, NOMID) with shared NLRP3 mutations; presentations range from intermittent fevers and rash to severe systemic disease.
    Key symptomsRecurrent or chronic fever, cutaneous rash often exacerbated by cold exposure, and systemic inflammatory features driven by IL‑1β.
    Therapeutic rationaleIL‑1 blockade (anakinra, canakinumab, rilonacept) reduces inflammation and normalizes acute‑phase reactants in CAPS patients.
    DIRA — additional definition/context entries
    Genetics and severityDIRA is autosomal‑recessive due to IL1RN gene mutations causing absent or dysfunctional IL‑1 receptor antagonist and severe neonatal disease.
    Remission maintenanceRilonacept is indicated for maintenance of remission after Kineret (anakinra) discontinuation; dosing includes loading and once‑weekly maintenance with possible escalation.
    Clinical endpointsRemission defined by diary score <0.5, CRP <0.5 mg/dL, absence of objective rash, and no radiologic evidence of active bone lesions in the pivotal study.
    Recurrent pericarditis (RP) — definition and clinical presentation
    DefinitionRecurrent pericarditis is recurrent inflammation of the pericardium, often presenting with pleuritic chest pain, pericardial friction rub, ECG changes, pericardial effusion, and elevated inflammatory markers (WBC, ESR, CRP).
    EpidemiologyAmong those treated for acute pericarditis, approximately 15–30% may experience recurrence; most recurrent cases are autoimmune/autoinflammatory in nature.
    Standard managementInitial treatment includes NSAIDs and colchicine; refractory cases may require corticosteroids, azathioprine, or anti‑IL‑1 agents such as rilonacept.
    Gout flare prevention during urate-lowering therapy initiation — definition/context
    DefinitionGout flare prevention during initiation of urate‑lowering therapy refers to use of weekly subcutaneous rilonacept (80–160 mg in trials) to reduce gout flares when starting allopurinol.
    Trial evidencePhase 3 trials (PRESURGE‑2, RESURGE) showed ≈70% fewer flares at Week 16 with weekly rilonacept versus placebo in patients with ≥2 flares in the prior 12 months.
    Population/contextEvaluated in adults initiating or continuing urate‑lowering therapy with a history of recurrent gout flares; not intended as routine acute flare therapy.
    FMF — colchicine-resistant/intolerant — definition/context
    DefinitionFamilial Mediterranean fever (FMF) is an autoinflammatory syndrome affecting Mediterranean populations; some patients are colchicine‑resistant or intolerant.
    Rilonacept evidenceRCTs including rilonacept showed probably no difference in number of attacks at 3 months versus placebo (moderate‑certainty evidence); additional high‑quality trials needed.
    Clinical roleRilonacept has been studied as an alternative for colchicine‑resistant/intolerant FMF but evidence is limited and not definitive.
    Schnitzler syndrome (SchS) — definition/context
    DefinitionSchnitzler syndrome (SchS) is a rare autoinflammatory disorder characterized by chronic urticarial rash and monoclonal gammopathy.
    Study findingsA prospective open‑label study (n=8) with a 300 mg loading dose then 160 mg weekly showed rapid clinical responses with reductions in CRP and SAA and good tolerability.
    Evidence levelEvidence is limited to small uncontrolled studies; suggests potential efficacy but remains investigational for routine coverage decisions.
    Subacromial bursitis — definition/context
    DefinitionSubacromial bursitis is inflammation of the subacromial bursa causing shoulder pain and impaired function.
    Rilonacept studyA randomized unblinded single‑center study (n=33) compared intra‑bursal rilonacept (160 mg) to triamcinolone (80 mg); both improved outcomes but triamcinolone was superior and rilonacept had more diarrhea and headache.
    ImplicationRilonacept is not demonstrated superior to standard corticosteroid injection and remains investigational for this indication.
    Systemic sclerosis (SSc) — definition/context
    DefinitionSystemic sclerosis (SSc) is a multisystem connective tissue disease affecting skin and internal organs, with variable involvement including interstitial lung disease and vascular manifestations.
    Rilonacept evidenceRilonacept appears in phase I/II trials reviewed in systematic literature but UpToDate reviews do not list rilonacept as a management option; no phase III evidence supports routine use.
    Current statusInvestigational in SSc based on limited early‑phase trial data; not an established therapeutic option in major reviews.
    Type 1 diabetes mellitus (T1DM) — definition/context and phase I trial note
    DefinitionType 1 diabetes mellitus (T1DM) is autoimmune destruction of pancreatic beta cells leading to insulin deficiency.
    Rilonacept trialA phase I trial (n=13) administered rilonacept subcutaneously for 26 weeks; treatment was well tolerated but C‑peptide declined and HbA1c increased, leading authors to conclude rilonacept is unlikely to be effective as a single agent to preserve beta‑cell function.
    Coverage implicationEvidence is insufficient to support routine use of rilonacept for preservation of beta‑cell function in recent‑onset T1DM.